OpenAI opens GPT-Rosalind academic access for eligible labs

News

OpenAI said eligible academic labs can get sponsored access to GPT-Rosalind and related tools for life sciences research.

OpenAI said on Thursday it is bringing GPT-Rosalind into academic research labs through a new Rosalind Academic Plan that offers eligible labs sponsored access to the company’s life sciences tools. The announcement extends the specialized model’s distribution after its earlier rollout for approved organizations, while leaving access constrained to eligible users rather than opening it broadly.

Evidence and context

The source material states only that the plan offers eligible academic labs sponsored access to GPT-Rosalind and tools intended to support life sciences research. OpenAI’s background materials describe GPT-Rosalind as a specialized reasoning model series for biology, drug discovery and translational medicine, with capabilities that include literature and evidence synthesis, target prioritization, protein and sequence analysis, medicinal chemistry, omics interpretation, hypothesis generation, experiment planning and wet-lab troubleshooting.

Enrichment supplied with the announcement places the release in a sequence of related product updates. On 2026-09-11, OpenAI said GPT-Rosalind had exited research preview with global availability for eligible organizations. On 2026-08-28, OpenAI introduced Rosalind Workbench, the surrounding research environment rather than the model itself. According to the background material, Workbench supports scientific viewers and guided FASTQ quality-control, bulk RNA-sequencing and single-cell workflows with researcher approval and traceable outputs.

The model’s capabilities have also been paired with benchmark results in OpenAI’s own developer reporting. The company said a June 3, 2026 update produced scores of 27.5% versus GPT-5.5’s 25.1% on MedChemBench, 21.6% versus 20.4% on GeneBench and 63.2% versus 55.8% on LabWorkBench. Those figures are model-benchmark results and do not demonstrate clinical efficacy, improved research outcomes or guaranteed discovery value.

Availability details remain somewhat inconsistent in the supplied material. OpenAI’s dated September 11, 2026 announcement says the model exited research preview, while the Help Center still labels it Research Preview. The dated announcement is the clearer statement on release status, but the access model remains restricted to approved organizations and, in this latest announcement, to eligible academic labs under the new sponsored plan.

The source material does not provide pricing, eligibility criteria, a launch date beyond the October 15, 2026 announcement, or any next verified catalyst.